Calcium channel blockers (versus unexposed)

Assisted deliveries (forceps, vacuum, ...)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13875
R54261		 Darcie - Isradipine, 2004 Forceps late pregnancy prospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 0.88 [0.15;5.16] C 5/39   2/14 7 39
ref
S13988
R54964		 Magee - Calcium blockers, 1996 Forceps at least 1st trimester excluded prospective cohort unexposed (general population or NOS) Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 0.65 [0.16;2.66] C
excluded (exposition period) 		3/28   8/51 11 28
ref
S13986
R54917		 Wide-Swensson - Isradipine, 1995 Forceps or vacuum extraction 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified 3.76 [0.74;19.19] C 7/47   2/45 9 47
ref
Total 2 studies 1.90 [0.46;7.85] 16 86
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Darcie - Isradipine, 2004Darcie - Isradipine, 2004 0.88[0.15; 5.16]73947%ROB confusion: seriousROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Wide-Swensson - Isradipine, 1995Wide-Swensson - Isradipine, 1995 3.76[0.74; 19.19]94753%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: lowROB mesure: lowROB reporting: moderate Total (2 studies) I2 = 28% 1.90[0.46; 7.85]16860.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.88[0.15; 5.16]739 -NADarcie - Isradipine, 2004 1 case control studiescase control studies 0 RCTRCT 3.76[0.74; 19.19]947 -NAWide-Swensson - Isradipine, 1995 1 Type of controls unexposed, sickunexposed, sick 1.90[0.46; 7.85]168628%NADarcie - Isradipine, 2004 Wide-Swensson - Isradipine, 1995 2 Tags Adjustment   - No  - No 0.88[0.15; 5.16]739 -NADarcie - Isradipine, 2004 1   - Randomisation  - Randomisation 3.76[0.74; 19.19]947 -NAWide-Swensson - Isradipine, 1995 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.90[0.46; 7.85]168628%NADarcie - Isradipine, 2004 Wide-Swensson - Isradipine, 1995 2 All studiesAll studies 1.90[0.46; 7.85]168628%NADarcie - Isradipine, 2004 Wide-Swensson - Isradipine, 1995 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.90[0.46; 7.85]168628%NADarcie - Isradipine, 2004 Wide-Swensson - Isradipine, 1995 20.510.01.0